The 2013 News Archive of Autifony Therapeutics: researching treatments for hearing disorders – tinnitus & age related hearing loss - & schizophrenia

2013 News Archive

Autifony Therapeutics wins Best Emerging Biotech Award at OBN Awards Dinner

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and serious disorders of the nervous system, announced that it was awarded the prize for Best Emerging Biotech at the OBN Annual Awards Dinner on 1st October.

Read more


Autifony Therapeutics Announces £2.75m Collaboration with Universities of Manchester and Newcastle to Progress a First-in-Class Drug for Schizophrenia

London, UK – 1 July 2013 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced a collaboration with research groups at the University of Manchester and Newcastle University to develop a novel, first-in-class Kv3 potassium channel modulator for the treatment of schizophrenia. The £2.75 million research collaboration is part-funded by the award of a £1.9 million grant to Autifony and the two Universities, by the UK’s innovation agency, the Technology Strategy Board. The award follows a successful funding application to the Biomedical Catalyst, jointly funded by the Technology Strategy Board and the Medical Research Council.

Read more


Autifony Therapeutics Initiates Phase I Study for Lead Product, AUT00063, for the Treatment of Hearing Loss and Tinnitus and Tops Up Series A Financing with Further 5.5 million Investment

London, UK, - 4 June 2013 - Autifony Therapeutics Limited ("Autifony"), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced the start of a Phase I clinical study of the novel, first-in-class Kv3 potassium channel modulator, AUT00063.

Read more